Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune checkpoint inhibitor-related pneumonitis with atypical radiologic features in a patient with anti-aminoacyl-tRNA synthetase antibody.
Ichihara S, Ogino H, Yoneda H, Haji K, Kagawa K, Murakami K, Mima M, Aoi Y, Mitsuhashi A, Tsukazaki Y, Yabuki Y, Ozaki R, Sato S, Nokihara H, Nishioka Y. Ichihara S, et al. Among authors: tsukazaki y. Respir Med Case Rep. 2022 Dec 15;41:101797. doi: 10.1016/j.rmcr.2022.101797. eCollection 2023. Respir Med Case Rep. 2022. PMID: 36583061 Free PMC article.
FoundationOne CDx detected an uncovered variant of epidermal growth factor receptor exon 19 deletion by Oncomine Dx target test in a patient with lung adenocarcinoma.
Takahashi H, Ogino H, Bando H, Mitsuhashi A, Tsukazaki Y, Yabuki Y, Ozaki R, Yoneda H, Sato S, Hanibuchi M, Nishioka Y. Takahashi H, et al. Among authors: tsukazaki y. Respir Med Case Rep. 2023 Jul 7;45:101893. doi: 10.1016/j.rmcr.2023.101893. eCollection 2023. Respir Med Case Rep. 2023. PMID: 37485237 Free PMC article.
Hypoxia-inducible factor-targeting therapy augmented the sensitivity to programmed death ligand-1 blockade by enhancing interferon-γ-induced chemokines in tumor cells.
Yabuki Y, Mitsuhashi A, Ogino H, Yoshida A, Nguyen NT, Yoneda H, Ozaki R, Tsukazaki Y, Morita Y, Nokihara H, Sato S, Shinohara T, Hanibuchi M, Nishioka Y. Yabuki Y, et al. Among authors: tsukazaki y. Int J Cancer. 2024 Dec 17. doi: 10.1002/ijc.35301. Online ahead of print. Int J Cancer. 2024. PMID: 39686841
Transformation of epidermal growth factor receptor mutated lung adenocarcinoma to small-cell carcinoma long after the cessation of tyrosine kinase inhibitor treatment: A case series and literature review.
Miyamoto K, Ogino H, Kakimoto T, Matsumura Y, Haji K, Mitsuhashi A, Morita Y, Tsukazaki Y, Yabuki Y, Ozaki R, Yoneda H, Sato S, Hanibuchi M, Bando Y, Nokihara H, Nishioka Y. Miyamoto K, et al. Among authors: tsukazaki y. Respir Med Case Rep. 2024 Jun 21;51:102076. doi: 10.1016/j.rmcr.2024.102076. eCollection 2024. Respir Med Case Rep. 2024. PMID: 39027818 Free PMC article.
Granulocyte colony-stimulating factor has the potential to attenuate the therapeutic efficacy of chemo-immunotherapy for extensive-stage small-cell lung cancer.
Tsukazaki Y, Ogino H, Okano Y, Kakiuchi S, Harada S, Toyoda Y, Matsumura Y, Ichihara S, Imakura T, Matsumoto R, Ozaki R, Ogawa E, Morita Y, Mitsuhashi A, Yabuki Y, Yoneda H, Hanibuchi M, Hase K, Takeuchi E, Haku T, Nishioka Y. Tsukazaki Y, et al. Int J Clin Oncol. 2024 Oct;29(10):1451-1460. doi: 10.1007/s10147-024-02586-0. Epub 2024 Jul 15. Int J Clin Oncol. 2024. PMID: 39009900
Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies.
Kozai H, Ogino H, Mitsuhashi A, Nguyen NT, Tsukazaki Y, Yabuki Y, Ozaki R, Yoneda H, Sato S, Hanibuchi M, Shinohara T, Nokihara H, Nishioka Y. Kozai H, et al. Among authors: tsukazaki y. Thorac Cancer. 2024 Feb;15(5):369-378. doi: 10.1111/1759-7714.15200. Epub 2023 Dec 26. Thorac Cancer. 2024. PMID: 38146645 Free PMC article.
40 results